Market Intelligence, Clinical Progress, and High-Purity Reagents for Ewing Sarcoma and Hematological Malignancy Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD99 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD99 ECD-Fc Recombinant Protein HEK293 expressed for native O-glycosylation. High purity (>95%), Endotoxin controlled (<1.0 EU/μg). Sequence Verified. |
View CD99 Products |
| Gene Delivery | CD99 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and cell-based binding assays. |
View CD99 Products |
| Benchmark Ab | Anti-CD99 Recombinant Antibody Derived from clinical/benchmark clones (e.g., clone 12E7/O662 sequence) for positive control and assay validation. |
View CD99 Products |
| Validator | CD99 siRNA Set Target-specific knockdown verification in target-positive cancer cell lines. |
View CD99 Products |
| Related Target A | CD99L2 (CD99 Antigen-Like 2) Highly homologous family member. Essential for specificity and off-target counter-screening panels. |
View CD99L2 Products |
| Related Target B | CD3 epsilon (CD3E) Crucial co-target for T-cell engaging bispecific antibody (TCB) development. |
View CD3E Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Conformation & Glycosylation | HEK293 mammalian expression host ensures correct post-translational O-glycosylation critical for CD99 epitope exposure. |
| Homolog Counter-Screening (Off-target Risk) | High-purity CD99L2 recombinant proteins available for cross-reactivity and specificity profiling. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies available as reference standards. |
| False Positives in Binding Assays | Sequence-verified siRNA pool included to validate target-specific knockdown in cell-based assays. |
Live CD99/MIC2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of CD99 (MIC2) is undergoing a significant renaissance. Historically utilized primarily as a diagnostic biomarker for Ewing sarcoma and T-lineage acute lymphoblastic leukemia (T-ALL), CD99 is now actively pursued as a viable therapeutic target. The race for CD99 therapeutics is intensifying, with major players shifting focus from traditional naked mAbs to modern antibody-drug conjugates (ADCs), bispecific antibodies, and CAR-T cell therapies. As first-generation therapies reach preclinical and early clinical validation, the next wave of R&D is targeting tumor-selective epitopes and logical-gated cell therapies to overcome on-target, off-tumor toxicities associated with normal tissue expression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugate (ADC) | Academic Institutes, Biotech Startups | Ewing Sarcoma, AML, T-ALL | Internalization Assay (Requires high-purity, native-glycosylated ECD-Fc protein to measure endocytosis kinetics) |
| Bispecific Antibody (e.g., CD99 x CD3) | Oncology-focused Biopharma | Hematological Malignancies | Dual-binding verification (Requires stable CD99-expressing cell lines via Lentivirus and recombinant CD3E/CD99 proteins) |
| CAR-T / CAR-NK Cell Therapy | Cell Therapy Developers | Ewing Sarcoma, Osteosarcoma | Specificity & Off-target screening (Requires CD99 vs. CD99L2 cross-reactivity panels to prevent off-tumor cytotoxicity) |